Competing strategies such as bispecific T-cell engagers (e.g., DLL3-targeting agents), antibody-drug conjugates, and cancer vaccines offer alternative mechanisms for engaging the immune system, often with less complex manufacturing and more manageable toxicity profiles. This evidence concerns the gene DLL3 and cancer.